



Tom/Volume 63; Numer/Number 6/2012
ISSN 0423–104X
Monika Puzianowska-Kuźnicka M.D., Ph.D., Department of Human Epigenetics, Mossakowski Medical Research Centre, Polish Academy of Sciences, 
5 Pawinskiego St., 02–106 Warsaw, Poland, tel.: +48 22 599 17 55, fax: +48 22 668 55 32, email: mpuzianowska@wum.edu.pl
Total and high molecular weight adiponectin and level- 
-modifying polymorphisms of ADIPOQ in centenarians
Całkowita i wysokocząsteczkowa adiponektyna oraz modyfikujące stężenie 
adiponektyny polimorfizmy genu ADIPOQ u stulatków 
Małgorzata Roszkowska-Gancarz1, Zbigniew Bartoszewicz2, Jacek Polosak1, 2, Alina Kurylowicz2,  
Marta Jonas2, Małgorzata Mossakowska3, Edward Franek2, Monika Puzianowska-Kuźnicka1, 2
1Department of Geriatrics and Gerontology, Medical Centre of Postgraduate Education, Warsaw, Poland 
2Department of Human Epigenetics, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland 
3Centenarians’ Programme, International Institute of Molecular and Cell Biology, Warsaw, Poland
Abstract
Introduction: Adiponectin demonstrates a protective role against the development of obesity, type 2 diabetes mellitus, and cardiovascular 
disease. The –11377C > G, –11391G > A, and –11426A > G promoter polymorphisms of ADIPOQ gene influence the level of circulating adi-
ponectin. We examined the level of total and high molecular weight (HMW) adiponectin in centenarians and associated it with biochemical 
parameters. We checked if the expression and concentration-modifying polymorphisms of ADIPOQ are associated with extreme longevity. 
Material and methods: Total and HMW adiponectin were examined using ELISA in 40 female centenarians. The frequencies of the ADI-
POQ polymorphisms were tested by restriction fragment length polymorphism in 148 centenarians, 414 young controls, in 207 myocardial 
infarction patients, and in 190 type 2 diabetes mellitus patients. 
Results: The mean concentration of total adiponectin in centenarians was 13.19 ± 1.37 mg/mL and of HMW adiponectin it was 9.17 ± 1.15 
mg/mL. They were positively correlated with HDL (r = 0.4696, p = 0.0025 and r = 0.3912, p = 0.015, respectively), and negatively with 
BMI (r = –0.3702, p = 0.034 and r = –0.3963, p = 0.025) and triglycerides (r = –0.346, p = 0.028 and r = –0.3227, p = 0.045). A very rare 
AA genotype of the –11391G > A polymorphism was significantly more common in centenarians than in young controls (p = 0.026) and, 
while compared to the GG genotype, it was associated with a 2.4-fold higher mean concentration of total adiponectin (26.53 ± 13.29 mg/ 
/mL v. 10.97 ± 4.28 mg/mL) and with an almost 3-fold higher mean HMW adiponectin (20.65 ± 12.72 mg/mL v. 7.36 ± 3.35 mg/mL). 
Conclusions: Serum adiponectin concentration in female centenarians is associated with biochemical parameters that are favourable for 
cardiovascular risk. We suggest that adiponectin might be of importance for extreme longevity.  (Endokrynol Pol 2012; 63 (6): 439–446)
Key words: total and high molecular weight (HMW) adiponectin, adiponectin gene (ADIPOQ), polymorphism, centenarians, myocardial infarction 
(MI), type 2 diabetes mellitus (DM2)
Streszczenie
Wstęp: Adiponektyna odgrywa ochronną rolę w patogenezie otyłości, cukrzycy typu 2 i chorób układu krążenia. Polimorfizmy –11377C > 
G, –11391G > A, i –11426A > G promotora ADIPOQ wpływają na stężenie adiponektyny. Autorzy zbadali stężenie całkowitej i wysokoczą-
steczkowej adiponektyny u stulatków i powiązali je z parametrami biochemicznymi. Sprawdzili, czy modyfikujące stężenie adiponektyny 
polimorfizmy ADIPOQ korelują z długowiecznością. 
Materiał i metody: Stężenia całkowitej i wielkocząsteczkowej adiponektyny oznaczono metodą ELISA u 40 stulatków. Częstość występo-
wania polimorfizmów ADIPOQ zbadano metodą analizy długości fragmentów restrykcyjnych u 148 stulatków, 414 młodych, zdrowych 
ochotników, 207 chorych po przebytym zawale serca i u 190 chorych z cukrzycą typu 2. 
Wyniki: Średnie stężenie całkowitej adiponektyny u stulatków wynosiło 13,19 ± 1,37 µg/ml, a adiponektyny wielkocząsteczkowej 
9,17 ± 1,15 µg/ml. Stężenia te pozytywnie korelowały ze stężeniem HDL (odpowiednio r = 0,4696, p = 0,0025 i r = 0,3912, p = 0,015), 
a negatywnie z BMI (r = –0,3702, p = 0,034 i r = –0,3963, p = 0,025) i stężeniem triglicerydów (r = –0,346, p = 0,028 i r = –0,3227, p = 0,045). 
Bardzo rzadki genotyp AA polimorfizmu –11391G > A występował znamiennie częściej u stulatków niż u młodych kontroli (p = 0,026) 
i, w porównaniu z genotypem GG, był związany z 2,4-krotnie wyższym stężeniem całkowitej adiponektyny (26,53 ± 13,29 µg/ml v. 10,97 
± 4,28 µg/ml) i prawie 3-krotnie wyższym stężeniem adiponektyny wielkocząsteczkowej (20,65 ± 12,72 µg/ml v. 7,36 ± 3,35 µg/ml). 
Wnioski: Korelacja pomiędzy stężeniami całkowitej i wielkocząsteczkowej adiponektyny u stulatków a korzystnymi z punktu widzenia 
ryzyka sercowo-naczyniowego parametrami biochemicznymi może świadczyć o udziale adiponektyny w promowaniu długowieczności. 
(Endokrynol Pol 2012; 63 (6): 439–446) 
Słowa kluczowe: całkowita i wielkocząsteczkowa (HMW) adiponektyna, gen adiponektyny (ADIPOQ), polimorfizm, stulatkowie, zawał mięśnia 
serca (MI), cukrzyca typu 2 (DM2)
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Introduction 
Adiponectin is a protein hormone secreted by adipo-
cytes. It has a higher expression in lean than in obese 
individuals and in women than in men [1]. Adiponectin 
is encoded by the ADIPOQ gene consisting of three 
exons and two introns. Many common promoter-, exon- 
and intron-located single nucleotide polymorphisms of 
this gene have been reported [2].
Adiponectin inhibits the expression of gluconeogenic 
enzymes and the rate of glucose production. It also stim-
ulates glucose utilisation and fatty acids oxidation [1]. 
Consequently, its level correlates positively with insulin 
sensitivity and with HDL level, and negatively with the 
levels of fasting glucose, insulin, total cholesterol, LDL, 
triglycerides, CRP, interleukin-6 and -18, and with TNFα 
[3–6]. A high level of circulating adiponectin protects 
against the development of obesity, insulin resistance, 
glucose intolerance, type 2 diabetes mellitus (DM2), 
hypertension, metabolic syndrome, atherosclerosis, and 
cardiovascular disease (CVD) [4, 6–9]. A protective role 
of high molecular weight (HMW) adiponectin against 
these diseases and a negative role of low molecular 
weight adiponectin on DM2 and CVD have recently 
been underlined [10–13]. However, in patients with 
prevalent CVD, hyperadiponectinaemia is not protec-
tive, but represents a compensatory mechanism and is 
a predictor of all-cause and of CVD mortality [8]. With 
advancing age, the level of total adiponectin increases 
in both sexes. In very old individuals it is significantly 
higher than in younger subjects [5,14]. 
The –11377C > G, –11391G > A, and –1426A > G 
polymorphisms in the ADIPOQ promoter influence the 
circulating adiponectin level: the presence of the G allele 
of the –11377C > G, the G allele of the –11391G > A, 
and the G allele of the –11426A > G polymorphisms are 
associated with a lower level of this hormone [15–19]. 
This phenomenon is the result of modulation of tran-
scription from the ADIPOQ promoter [16–19]. 
The aims of the study were to evaluate the level of 
total and HMW adiponectin and its associations with 
biochemical parameters in centenarians and to deter-
mine if the expression level-modifying polymorphisms 
of the ADIPOQ are associated with extreme longevity.
Material and methods
Study participants
All study subjects were ethnically homogenous Polish 
Caucasians. Analysis of the ADIPOQ genetic variants 
was performed in four groups: 148 centenarians 
(99.6–107.2 years old, mean ± SD 101.1 ± 1.2 years 
old, 129 females and 19 males), participants in the 
‘PolStu2001’ study [20]; a young control group con-
sisting of 414 blood donors and volunteers (18 to 45 
years old, mean 27.1 ± 7.3, 233 females and 181 males, 
with only 79 individuals who were 35 years old or 
older) with no signs and symptoms of any disease; 
a myocardial infarction (MI) control group consisting 
of 207 patients (first MI at the age of 28-55, mean age 
at first MI 47.1 ± 5.2, 53 females and 154 males); and 
a type 2 diabetes mellitus (DM2) control group con-
sisting of 190 patients (diagnosed at the age of 26-55, 
mean age at diagnosis 47.7 ± 5.6, 120 females and 70 
males). Some of the MI and DM2 control patients were 
participants in the ‘PolSenior ’ study [21].
Due to a limited availability of plasma, total and HMW 
adiponectin concentrations were measured only in 40 pre-
selected centenarian women (100 to 104.7 years old, mean 
100.9 ± 0.96). The selection was based on the availability of 
the biological material and on the genotype of the ADIPOQ 
polymorphisms they carried; special attention was paid 
to ensure that as many individuals as possible with rare 
variants of the studied polymorphisms were included 
in this study. Following this procedure, all but one (GG 
of the –11426A > G) genotypes of the tested ADIPOQ 
polymorphisms were represented in this group. Five out 
of 40 centenarian women did not take any medications. 
Seventeen were treated with one to three medications, 
usually sedatives, drugs improving brain blood flow, vita-
mins, laxatives, and painkillers. The remaining 18 women 
were treated with four or more medications; in addition 
to the supporting drugs (the same as mentioned above), 
these were various drugs used to treat hypertension and 
cardiovascular disease. 
All participants gave written informed consent 
for participation in the study. The study protocol was 
approved by the Bioethical Committee of the Medical 
University of Warsaw. 
Basic biochemical parameters
Basic biochemical parameters in serum/plasma of the 40 
abovementioned centenarian women were examined 
in the diagnostic laboratory of the Infant Jesus Teaching 
Hospital of the Medical University of Warsaw, according 
to a routine procedure. 
Analysis of total and high molecular weight  
adiponectin concentrations
Concentrations of total and HMW adiponectin were 
measured with an Adiponectin (Multimeric) ELISA kit 
(ALPCO Diagnostics, Salem, NH, USA) according to the 
manufacturer’s protocol.
DNA isolation and analysis of restriction  
fragment length polymorphisms 
Blood samples of 4 ml were used to isolate the 
genomic DNA; this was performed by a salting-out 
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procedure [22]. The concentration and purity of DNA 
were assessed by UV spectroscopy. Genotyping of 
the selected polymorphisms in the ADIPOQ was 
done by PCR amplification followed by digestion 
with an appropriate restriction enzyme (restriction 
fragment length polymorphism method, RFLP). PCR 
conditions were: initial denaturation at 94oC for 5 
min followed by 40 cycles of 94oC for 30 s, 56oC or 
63oC for 30 s, 72oC for 30 s, final elongation at 72oC 
for 5 min. Each 12.5 µl reaction contained 50 ng of 
the genomic DNA, 2.0 mM MgCl2, 10 pmol of each 
primer, 0.25 mM of each dNTP, and 1 unit of Taq 
polymerase in a buffer supplied by the manufacturer 
(Invitrogen, Carlsbad, CA, USA). Other details of 
the PCR-RFLP conditions are shown in Table I. The 
restriction fragments obtained were visualised on 
2–3% agarose gels. 
Statistical analysis
The genotype distribution was analysed using the 
Web-Assotest programme (available at: http://www.
ekstroem.com/assotest/assotest.html) assuming domi-
nant and recessive models of inheritance. Under each 
model, the odds ratio (OR) with a 95% confidence 
interval (CI) and the p value for an association were 
calculated. The Hardy-Weinberg equilibrium was 
assessed by a c2 test.
The impact of genotypes on total and HMW 
adiponectin concentrations was calculated using the 
Statistica software package (StatSoft, Tulsa, OK, USA). 
Normality of distribution and homogeneity of the vari-
ance were checked with the Shapiro-Wilk and Levene’s 
tests, respectively. Where these conditions were not 
met, analyses were performed with non-parametric 
Kruskal-Wallis ANOVA (ad-hoc) and U Mann-Whitney 
(post hoc) tests.
Correlations between quantitative values were per-
formed with the Spearman correlation test (Statistica 
software package).
For all tests, the level of significance was established 
at 0.05.
Results
Concentrations of total and high molecular 
weight adiponectin and their associations  
with biochemical parameters in centenarians
Adiponectin concentrations were measured in 40 
female centenarians. The ranges and the median values 
of BMI, fasting glucose, insulin, total cholesterol, HDL, 
and triglycerides in these centenarians are shown in Ta-
ble II. The mean concentration of total adiponectin was 
13.19 ± 1.37 µg/mL (median 10.82 µg/mL, 1st quartile 8.86, 
3rd quartile 16.17), and the mean concentration of HMW 
adiponectin was 9.17 ± 1.15 µg/mL (median 7.47 µg/mL, 
1st quartile 5.36, 3rd quartile 11.54). Total and HMW adi-
ponectin were strongly correlated (r = 0.8956, p < 0.0001). 
The mean HMW to total adiponectin ratio was 0.695.
Total and HMW adiponectin were positively correlated 
with the level of HDL (r = 0.4696, p = 0.0025 and r = 
= 0.3912, p = 0.015, respectively) and negatively with BMI 
(r = –0.3702, p = 0.034 and r = –0.3963, p = 0.025) and 
with the level of triglycerides (r = –0.346, p = 0.028 and 
r = –0.3227, p = 0.045, respectively). No other significant 
correlations with clinical parameters were found. No corre-
lation with the number or type of medications was noticed.
Distribution of the ADIPOQ –11377C > G, 
–11391G > A, and –11426A > G polymorphisms 
in centenarians and in young controls 
Genotype frequencies of the ADIPOQ polymorphisms in 
centenarians and in young controls are shown in Table III. 
Table I. PCR-RFLP conditions used for the analysis of the –11377C>G, –11391G>A and –11426A > G polymorphisms in the 
ADIPOQ gene
Tabela I. Warunki PCR-RFLP stosowane podczas analizy polimorfizmów –11377C>G, –11391G>A i –11426A > G w genie 
ADIPOQ
Polymorphism PCR Primers Tm PCR product Restriction Alleles
–11377C > G F: 5’GCTCTGTGTGGACTGTGGAG3’ 63°C 302 bp HhaI, 37°C, 3 h   C: 302 bp
R: 5’AGAAGCAGCCTGGAGAACTG3’   G: 182, 120 bp
–11391G > A F: 5’GCTCTGTGTGGACTGTGGAG3’ 63°C 278 bp MspI, 37°C, 3 h   G: 166, 112 bp
R: 5’CTGCCACCCACTTAGGTGTT3’   A: 278 bp
–11426A > G F: 5’CATCTCAACGGCCTAATGTG3’ 56°C 273 bp TasI, 65°C, 3 h   A: 185, 62, 26 bp
R: 5’AAGCCACACATTCTGATGAACTAA3’   G: 185, 88 bp
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The initial analysis was aimed at establishing the pattern of 
their distribution in both sexes. Upon analysis of the young 
controls group, we found that the tested polymorphisms 
were distributed equally in males and in females. 
Next, we established genotype frequencies of these 
polymorphisms in both age groups. We found that the 
AA genotype of the –11391G > A polymorphism was 
significantly more common in centenarians than in 
young controls (p = 0.026, 2.01% v. 0.24%, OR = 8.48 
[95% CI 1.20–59.60]), and in centenarians without MI 
and/or DM2 (n = 130) than in young controls (p = 
0.031, 2.29% v. 0.24%, OR = 9.68 [95%CI 1–93.87]). The 
–11377C > G and –11426A > G polymorphisms were 
distributed similarly in all tested groups. 
Associations of the ADIPOQ –11377C > G, 
–11391G > A, and –11426A > G polymorphisms 
with the mean concentrations of total and high 
molecular weight adiponectin in centenarians
Almost all genotypes of the –11377C > G, –11391G > A, 
and –11426A > G polymorphisms were associated with 
the similar mean concentrations of total and HMW 
adiponectin in the tested group of 40 female centenar-
ians (Table IV). However, we noticed that a very rare 
AA genotype of the –11391G > A polymorphism was 
associated with a 2.4-fold higher mean concentration of 
total adiponectin and with an almost 3-fold higher mean 
HMW adiponectin compared to the values associated 
with the GG genotype (26.53 ± 13.29 µg/mL v. 10.97 ± 
Table II. Values of the basic metabolic parameters (fasting) in 40 female centenarians who underwent testing for total and 
HMW adiponectin
Tabela II. Wartości podstawowych parametrów metabolicznych oznaczone na czczo u 40 kobiet z grupy stulatków, u których 
badano stężenia całkowitej i wielkocząsteczkowej adiponektyny 
Range Median (1st quartile, 3rd quartile) Mean ± SD
BMI* [kg/m2] 15.75–33.20 22.96 (20.92, 26.25) 23.72 ± 4.02
Glucose [mg/dL] 34–315 87 (80.75, 95.75) 95.30 ± 42.42
Insulin [pmol/L] 9.86–435 32.15 (23.17, 68.95) 57.21 ± 72.10
Total cholesterol [mg/dL] 127–287 201 (165.75, 242) 201.65 ± 44.82
HDL [mg/dL] 32–117 67 (48, 82) 64.41 ± 20.66
Triglycerides [mg/dL] 47–247 104.5 (74, 135) 109.62 ± 44.49
*calculated for 33 centenarians
Table III. Frequencies of the examined genotypes in centenarians, young controls, MI patients, and in DM2 patients
Tabela III. Częstości badanych genotypów u stulatków, zdrowych, młodych kontroli, chorych po przebytym zawale serca 
i chorych z cukrzycą typu 2
–11377C > G –11391G > A –11426A > G
gt % n gt % n gt % n
Centenarians CC 48.65 72 GG 81.89 122 AA 82.99 122
CG 43.92 65 GA 16.10 24 AG 16.32 24
GG 7.43 11 AA 2.01 3 GG 0.69 1
Young controls CC 51.69 214 GG 85.51 354 AA 84.30 349
CG 38.65 160 GA 14.25 59 AG 14.97 62
GG 9.66 40 AA 0.24 1 GG 0.73 3
MI patients CC 50.48 105 GG 86.90 179 AA 81.82 171
CG 41.82 87 GA 12.62 26 AG 17.22 36
GG 7.70 16 AA 0.48 1 GG 0.96 2
DM2 patients CC 49.21 93 GG 88.89 168 AA 81.08 150
CG 43.92 83 GA 9.52 18 AG 18.38 34
GG 6.88 13 AA 1.59 3 GG 0.54 1
gt: genotype, %: percentage, n: number of examined samples
443













± 4.28 µg/mL and 20.65 ± 12.72 µg/mL v. 7.36 ± 3.35 µg/ 
/mL for total and HMW adiponectin, respectively). 
Distribution of the ADIPOQ –11377C > G, 
–11391G > A, and –11426A > G polymorphisms 
in myocardial infarction patients and in type 2 
diabetes mellitus patients
Genotype frequencies of the ADIPOQ polymorphisms 
in MI patients and DM2 patients are shown in Table III. 
There was a trend toward significant difference in the 
frequency of the AA genotype of the –11391G > A 
polymorphism between DM2 patients and young 
controls (p = 0.072, 1.59% v. 0.24%, OR = 6.66 [95% CI 
0.69–64.46]). The difference between DM2 patients and 
centenarians was not significant. The –11377C > G and 
–11426A > G polymorphisms were equally distributed 
in DM2 patients, young controls, centenarians, and 
centenarians without DM2. 
No significant differences were found in the dis-
tribution of the tested polymorphisms between MI 
patients, young controls, centenarians, and centenar-
ians without MI. 
Table IV. Association of the ADIPOQ genotypes with total and HMW adiponectin in female centenarians
Tabela IV. Związek genotypów genu ADIPOQ ze stężeniem całkowitej i wielkocząsteczkowej adiponektyny u kobiet-stulatek
Range Median 
(1st quartile, 3rd quartile)
Mean ± SD p value
Total adiponectin [μg/mL]
–11377C > G ns
gt n
CC 13 5.30–35.90 17.10 (10.3, 19.06) 17.19 ± 9.86
CG 23 5.61–19.98 10.2 (7.62, 14.06) 11.17 ± 4.48
GG 4 10.51–15.24 10.71 (10.51, 12.0) 11.79 ± 2.31
–11391G > A ns
gt n
GG 26 5.30–19.98 10.51 (7.64, 12.68) 10.97 ± 4.25
GA 12 5.46–34.67 14.96 (10.03, 18.83) 15.78 ± 8.20
AA 2 17.10–35.90 26.50 (21.80, 31.20) 26.50 ± 13.29
–11426A > G ns
gt n
AA 31 5.61–35.90 10.92 (8.99, 15.86) 13.49 ± 7.44
AG 9 5.30–19.52 10.71 (9.01, 19.06) 12.14 ± 5.69
HMW adiponectin [μg/mL]
–11377C > G ns
gt n
CC 13 3.04–29.67 11.74 (5.68, 14.68) 12.67 ± 8.90
CG 23 3.09–15.14 6.90 (4.92, 9.84) 7.58 ± 3.32
GG 4 5.72–10.97 6.87 (6.14, 8.34) 7.61 ± 2.35
–11391G > A ns
gt n
GG 26 3.04–15.14 6.44 (4.94, 8.60) 7.38 ± 3.37
GA 12 3.81–28.89 11.07 (6.49, 12.36) 11.26 ± 7.10
AA 2 11.64–29.67 20.65 (16.15, 25.16) 20.65 ± 12.75
–11426A > G ns
gt n
AA 31 3.09–29.67 7.83 (5.12, 11.36) 9.45 ± 6.41
AG 9 3.04–13.75 6.33 (5.68, 11.55) 7.98 ± 3.79
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Discussion and conclusions
Previous reports concerning adiponectin in centenarians 
have established this level approximately at 17 µg/mL and 
at 20 µg/mL [14, 23]. In this study, we found that the mean 
total adiponectin in female centenarians is approximately 
13 µg/mL; even though lower than previously reported, 
this is still higher than in all younger age groups: the mean 
concentration of this hormone in healthy humans has been 
reported to be approximately 5–11 µg/mL at 20–45 years 
old [12, 14], 6.5–10 µg/mL at 55–70 years old [14, 24], and 
8–11 µg/mL at 80-90 years old [12]. The mean concentration 
of HMW adiponectin in healthy humans was reported 
to be 3–7 µg/mL in young and elderly and 3–9 µg/mL in 
old humans [10, 12], with its level being higher in females 
than in males. To date, HMW adiponectin had not been 
measured in centenarians; we report here that its mean 
concentration in females of this age group is approximately 
9 µg/mL. The mean ratio of HMW to total adiponectin in 
centenarians is 0.695, which is higher than that of younger 
age groups [11, 12, 25].
Altogether, these figures show that extreme longev-
ity is associated with the highest concentrations of total 
and HMW adiponectin and with the highest HMW/ 
/total adiponectin ratio. This phenomenon might have 
a number of explanations. 
Firstly, high concentrations of total and HMW adi-
ponectin truly promote longevity. It should be noted 
though, that the mechanisms of such action of this 
hormone are not completely clear. As described in the 
Introduction, it decreases the risk of development of 
life-shortening diseases, but we should keep in mind 
that total and HMW adiponectin were consistently 
higher in centenarians than in individuals younger than 
90 years old, who were free of such diseases (healthy 
ageing). Therefore, other, yet unknown, functions might 
be also involved in the longevity-promoting action of 
adiponectin. 
Secondly, posttranslational modifications, such as 
proteolytic cleavage, glycosylation, and hydroxylation 
that affect the conformation and stability of adiponectin 
might be increasingly inadequate during ageing [26–28]. 
This might ‘force’ adipose cells to overexpress adiponec-
tin in order to compensate for its ageing-associated 
decrease in activity [29, 30]. 
Thirdly, not adiponectin itself, but expression and 
activity of its receptors might be more important in 
ageing. Indeed, it has been shown that expression of 
adiponectin receptors is inadequate in aged humans 
and animals [30, 31]; this could result in a compensatory 
increase of expression of the ligand.
It has still not been established whether HMW 
adiponectin testing should be used routinely in clini-
cal practice. It clearly has a great cognitive value and 
helps to elucidate the mechanisms connecting obesity 
and obesity-related diseases. Available data strongly 
suggests that HMW adiponectin is a better predictor 
than total adiponectin in assessing the risk of metabolic 
and cardiovascular diseases [10–12]. However, before 
an HMW adiponectin test is recommended for routine 
use, these observations require validation using larger 
groups of healthy and diseased individuals. This is es-
pecially important because even well-characterised total 
adiponectin is not an element of routine diagnostics. 
The –11377C > G, –11391G > A, and v11426A > G 
promoter polymorphisms of the adiponectin-encoding 
ADIPOQ gene have been shown to influence the level of 
circulating adiponectin [15, 19] and to be associated with 
impaired glucose metabolism, metabolic syndrome, and 
with CVD, diseases that negatively influence longev-
ity. For example, it has been shown that the G allele 
of the –11377C > G polymorphism is correlated with 
an increased risk of DM2 [15], increased carotid artery 
intima-media thickness [18], a higher extent of coro-
nary stenosis, and with an increased risk of vascular 
events and of CVD [32]. The G allele of the –11391G 
> A polymorphism is correlated with obesity, a higher 
fasting insulin level, insulin resistance, homeostatic 
model assessment (HOMA) index, and with DM2 [15]. 
Finally, the G allele of the –11426A > G polymorphism 
showed association with a higher fasting glucose level 
and with DM2 [33].
We found that the AA genotype of the –11391G 
> A polymorphism was more common in cente-
narians (2.01%) than in young controls (0.24%). At 
first, this finding seemed to be unimportant due to 
the low frequency of this genotype in the analysed 
population. However, it gains significance when 
interpreted together with the findings of other 
authors. The frequency of the AA genotype of the 
–11391G > A polymorphism was 1% in a cohort of 
French and Italian children and adolescents [34], 1% 
in non-Hispanic white teenage US citizens [35], 0% 
in teenage African Americans [35], 0.7% in elderly 
French Caucasians without DM2 [15], and 0.08% in 
elderly British Caucasians without cardiovascular 
disease [32]. Clearly, the frequency of this variant 
seems to be highest in centenarians. In addition, we 
found that in centenarians it co-existed with higher 
total adiponectin concentrations compared to the GG 
genotype. This corroborates previous observations 
performed in younger individuals, in whom such 
a correlation was found and was significant [15, 32, 
34, 35]. However, our finding that the AA genotype 
of the –11391G > A polymorphism co-exists with a 
higher concentration of HMW adiponectin has never 
previously been reported and should be evaluated in 
other populations. Finally, we observed that the AA 
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genotype of the –11391G > A polymorphism is more 
common in DM2 patients (1.59%) than in healthy 
controls (0.24%). This corroborates the findings of 
Vasseur et al., who showed that in elderly DM2 pa-
tients its frequency was 1.5% v. 0.7% in age-matched 
controls [15].
Nevertheless, this work should be viewed as 
preliminary. First, the analysed groups are relatively 
small; the analysis of large groups would have pro-
duced results with more statistical power. A Bon-
ferroni correction is typically applied to decrease 
the risk of obtaining false-positive results due to 
the small size of the groups and to multiple test-
ing; however, the value of this correction is under 
criticism [36, 37]; it is considered too restrictive, and 
its application lowers the chance of publication of 
negative or marginally significant results, causing 
a publication bias. Therefore, we chose not to ap-
ply it and to present both marginally positive and 
negative results, since this will undoubtedly be 
useful for further meta-analyses. Second, sex distri-
bution in the groups analysed for the frequency of 
polymorphisms was unequal; this is however only 
a theoretical limitation, since we checked the sex-
related distribution of the ADIPOQ polymorphisms 
in the Y group composed of healthy individuals and 
found that they were equally distributed in females 
and in males. Also, HMW adiponectin was analysed 
only in female centenarians; it is unclear whether 
its concentration follows the same pattern in male 
centenarians. This might not be so, because there are 
suggestions that HMW adiponectin is lower in males 
than in females due to the inhibitory action of tes-
tosterone on the HMW form release from adipocytes 
[38]. Finally, due to a low number of individuals with 
rare genetic variants of ADIPOQ (discussed above), 
correlations between these genotypes and total and 
HMW adiponectin have low statistical power and 
demand confirmation using a much larger group 
of individuals. 
Taken together, our data shows that in females ex-
treme longevity is associated with high concentrations 
of total and HMW adiponectin, as well as with a ratio 
of HMW to total adiponectin higher than in all younger 
age groups. Serum adiponectin in female centenarians 
is associated with biochemical parameters that lower 
cardiovascular risk. We also showed that only a very 
rare AA genotype of the 11391G > A ADIPOQ promoter 
polymorphism, but not the genotypes of the –11377C 
> G and –11426A > G polymorphisms, might be as-
sociated with longevity, and we speculate that this is 
so regardless of its association with an increased risk 
of DM2. 
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